242 related articles for article (PubMed ID: 15905205)
1. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
3. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
[TBL] [Abstract][Full Text] [Related]
4. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients.
Murata M; Tagawa M; Kimura H; Kakisawa K; Shirasawa H; Fujisawa T
Int J Oncol; 1998 Mar; 12(3):577-81. PubMed ID: 9472095
[TBL] [Abstract][Full Text] [Related]
6. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
Hu Y; McDermott MP; Ahrendt SA
Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
8. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.
Anna L; Holmila R; Kovács K; Gyorffy E; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Husgafvel-Pursiainen K; Schoket B
Mutagenesis; 2009 Nov; 24(6):475-80. PubMed ID: 19643813
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer.
Marsit CJ; Hasegawa M; Hirao T; Kim DH; Aldape K; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT
Cancer Res; 2004 Dec; 64(23):8702-7. PubMed ID: 15574780
[TBL] [Abstract][Full Text] [Related]
10. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer.
Hirao T; Nelson HH; Ashok TD; Wain JC; Mark EJ; Christiani DC; Wiencke JK; Kelsey KT
Cancer Res; 2001 Jan; 61(2):612-5. PubMed ID: 11212258
[TBL] [Abstract][Full Text] [Related]
11. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
12. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival.
Marsit CJ; Wiencke JK; Nelson HH; Kim DH; Hinds PW; Aldape K; Kelsey KT
Cancer Genet Cytogenet; 2005 Oct; 162(2):115-21. PubMed ID: 16213358
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Fontanini G
Oncol Rep; 2008 Mar; 19(3):771-3. PubMed ID: 18288414
[TBL] [Abstract][Full Text] [Related]
14. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.
Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537
[TBL] [Abstract][Full Text] [Related]
15. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
[TBL] [Abstract][Full Text] [Related]
16. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
17. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis.
Buller RE; Sood A; Fullenkamp C; Sorosky J; Powills K; Anderson B
Cancer Gene Ther; 1997; 4(4):239-45. PubMed ID: 9253509
[TBL] [Abstract][Full Text] [Related]
18. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population.
Sreeja L; Syamala V; Raveendran PB; Santhi S; Madhavan J; Ankathil R
Cancer Invest; 2008 Feb; 26(1):41-6. PubMed ID: 18181044
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
20. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
